Telmisartan detailed information

	WikiDoc Resources for Telmisartan detailed information
Articles
Most recent articles on Telmisartan detailed information Most cited articles on Telmisartan detailed information Review articles on Telmisartan detailed information Articles on Telmisartan detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Telmisartan detailed information Images of Telmisartan detailed information Photos of Telmisartan detailed information Podcasts & MP3s on Telmisartan detailed information Videos on Telmisartan detailed information
Evidence Based Medicine
Cochrane Collaboration on Telmisartan detailed information Bandolier on Telmisartan detailed information TRIP on Telmisartan detailed information
Clinical Trials
Ongoing Trials on Telmisartan detailed information at Clinical Trials.gov Trial results on Telmisartan detailed information Clinical Trials on Telmisartan detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Telmisartan detailed information NICE Guidance on Telmisartan detailed information NHS PRODIGY Guidance FDA on Telmisartan detailed information CDC on Telmisartan detailed information
Books
Books on Telmisartan detailed information
News
Telmisartan detailed information in the news Be alerted to news on Telmisartan detailed information News trends on Telmisartan detailed information
Commentary
Blogs on Telmisartan detailed information
Definitions
Definitions of Telmisartan detailed information
Patient Resources / Community
Patient resources on Telmisartan detailed information Discussion groups on Telmisartan detailed information Patient Handouts on Telmisartan detailed information Directions to Hospitals Treating Telmisartan detailed information Risk calculators and risk factors for Telmisartan detailed information
Healthcare Provider Resources
Symptoms of Telmisartan detailed information Causes & Risk Factors for Telmisartan detailed information Diagnostic studies for Telmisartan detailed information Treatment of Telmisartan detailed information
Continuing Medical Education (CME)
CME Programs on Telmisartan detailed information
International
Telmisartan detailed information en Espanol Telmisartan detailed information en Francais
Business
Telmisartan detailed information in the Marketplace Patents on Telmisartan detailed information
Experimental / Informatics
List of terms related to Telmisartan detailed information

Telmisartan detailed information
Clinical data
Pregnancy; category	D (Au), D (U.S.);
Routes of; administration	Oral
ATC code	C09CA07 (WHO) ;
Legal status
Legal status	S4 (Au), POM (UK), ℞-only (U.S.);
Pharmacokinetic data
Bioavailability	42–100%
Protein binding	≥99.5%
Metabolism	Minimal hepatic
Elimination half-life	24 hours
Excretion	Faecal 97%
Identifiers
	IUPAC name 2-[4-[[4-methyl-6-(1-methylbenzoimidazol-2-yl)-; 2-propyl-benzoimidazol-1-yl]methyl]phenyl]; benzoic acid;
CAS Number	144701-48-4;
PubChem CID	65999;
DrugBank	APRD01247;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C33H30N4O2
Molar mass	514.617 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

For patient information, click here

Overview

Telmisartan (INN) (Template:PronEng) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. It is marketed under the trade names Micardis (Boehringer Ingelheim) and Pritor or Kinzal (Bayer Schering Pharma).

Pharmacology

Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT₁) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure.

New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials. In India it is available in the name of Telma by Glenmark Pharma according to www.sureshjain.com.

Clinical use

In India RANBAXY also markets it under the name of 'Teleact 20 mg"

External links

Template:Angiotensin II receptor antagonists Template:SIB

nl:Telmisartan

Template:WikiDoc Sources

Clinical data

Pregnancy category	D (Au), D (U.S.)
Routes of administration	Oral
ATC code	C09CA07 (WHO)
Legal status
Legal status	S4 (Au), POM (UK), ℞-only (U.S.)
Pharmacokinetic data
Bioavailability	42–100%
Protein binding	≥99.5%
Metabolism	Minimal hepatic
Elimination half-life	24 hours
Excretion	Faecal 97%
Identifiers
IUPAC name 2-[4-[[4-methyl-6-(1-methylbenzoimidazol-2-yl)- 2-propyl-benzoimidazol-1-yl]methyl]phenyl] benzoic acid
CAS Number	144701-48-4
PubChem CID	65999
DrugBank	APRD01247
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₃₃H₃₀N₄O₂
Molar mass	514.617 g/mol